Laverdia

Laverdia Ca-1 (verdinexor) was originally developed by a company working on human cancer treatments. It was discovered that this medicine worked better in dogs than in humans and Anivive Lifesciences, purchased the medication. Since the purchase, they have been working toward full FDA approval.

Published by Amber L. Drake

Dr. Amber L. Drake is a celebrated author and a distinguished cancer specialist, renowned for her comprehensive research in canine cancer prevention and nutrition. She is widely recognized for her commitment to helping dogs lead long and joyful lives, as well as for her contributions to veterinary medicine education. As the CEO of Canine Companions Co., the Founder of the Drake Dog Cancer Foundation and Academy, and the Co-Founder of Preferable Pups, she has become a respected and influential figure in the canine community, earning the admiration and respect of dog enthusiasts around the globe.